Weekly Update: April 24th, 2023
These days it’s like, Man what else can go wrong….
The good news is that this latest upheaval in the Sudan is not likely to roil markets.
“The main products that Sudan exported to United States are Insect Resins ($18.6M), Paintings ($271k), and Antiques ($99.1k). During the last 26 years the exports of Sudan to United States have decreased at an annualized rate of 3.36%, from $46.7M in 1995 to $19.2M in 2021.”
“The main products that United States exported to Sudan are Wheat ($69.2M), Sorghum ($26.8M), and Other Pure Vegetable Oils ($8.15M). During the last 26 years the exports of United States to Sudan have increased at an annualized rate of 2.54%, from $71.4M in 1995 to $137M in 2021.”
Those numbers are just a rounding error in terms of our markets. Hopefully we’ll not get sucked into another war fighting someone else’s battles. I doubt that is the case here and unlike the Ukraine I don’t see how this could spell a national security risk.
More likely that the Bed Bath and Beyond bankruptcy will have far more reaching effects. To see another of our major old school retailers go down is certainly disheartening, but maybe this is the new world order that doesn’t see a place for brick and mortar any longer. We’ll see I guess.
Oh yea, then there is another issues. The credit worthiness of our banks
Moody’s Investor Services on Friday issued downgrades for 11 regional investors after the credit agency signaled last month that it was conducting reviews of some banks following the collapse of tech-centric Silicon Valley Bank.
Utah-based Zions Bancorporation was among the group of financial institutions that received downgrades.
Still the best place to put your money is under your mattress I guess.
The 21st Century Investment Bank Capital Raises + Strategic Advisory
Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.
Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.
For more information go to: www.DonaldCapital-NY.com
4-19-2023 Can B Corp. (OTC CANB)
Reports Growth of 45% to Company All-Time High $6.7 Million Annual Revenue
Led by Significant Increase in Duramed
Adjusted EBITDA Loss Decreased by 25% to $2.1 Million
HICKSVILLE, NY, April 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company’s financial results for the twelve months ended December 31, 2022.
Key Financial Highlights for 2022
- Revenue increased 45% to $6.7 million.
- Gross profit decreased 13% to $2.6 million.
- Gross margin decreased to 39.1%, due to a higher revenue percentage mix from Duramed.
- Adjusted EBITDA loss decreased by 25% to $2.1 million.
- Accounts receivable at $6.6 million.
- Inventory at $2.0 million.
- Total assets at $15.6 million.
- Total stockholders’ equity at $2.7 million.
Coeptis Therapeutics Holdings, Inc. NASDAQ (COEP)
Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors
Clinical data from AML Clinical Trial Expected during 2H 2023
WEXFORD, Pa. , April 18, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023, to negotiate towards the acquisition or license of assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. Deverra Therapeutics is currently advancing clinical programs investigating these technologies in relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with respiratory viral infections.
3-15-2023 Can B Corp. (OTC CANB)
Can B Corp. Completes Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange
HICKSVILLE, NY, March 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products and durable medical devices, is pleased to announce it has successfully completed a corporate debt restructuring.
Through the restructuring, Can B raised $1.55 million of new capital and extended previously due notes payable totaling $7.0 million to September 1, 2023, and December 31, 2024. Specifically, three Promissory Notes issued to three funds in early 2022 and three Promissory Notes issued to three private investors in late 2022 were restructured to extend maturity dates to late in 2023 to give the Company an additional window to deploy the capital from the new raise.
3-6-2023 International Food and Beverage (OTC IFBC)
See the latest investor package. Dino is really getting traction.
2-15-2023 Antibe Therapeutics, Inc. (OTCQX ATBPF)
Antibe Reports Q3 2023 Interim Financial and Operating Results
– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management
– Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months
– Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway
TORONTO, February 15, 2023–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.
1-31-2023 Coeptis Therapeutics, Inc. (OTC COEP)
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program
Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers
WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology. SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors.
Check out our latest commercial properties including an Amazing Private Island or Resort Development Property in Panama
Message me on Linkedin and check our latest commercial listings:
Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:
|April 24, 2023 COMPANY QUOTES, LISTINGS RESEARCH AND NEWS |
Coeptis Therapeutics, Inc. Ecrid, Inc (ECDD) Profile
Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News
Can B Corp (CANB) Profile News
Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News
International Food and Beverage Profile
Large-Cap Growth Rampage Could Be Creating Small-Cap Value Opportunities
April 18, 2023 by Herb Blank
In January, we published “Rotating Regimes – What to Plan For in 2023.” At that time, we recounted that the 2022 US Stock Market was a conflagration that wiped out almost everything in its path with the exception of a few industries and ETFs. At that time, we reported that two Benchmark ETFs we track, the Nasdaq-100 ETF (QQQ) and the Russell 1000 Growth ETF (IWF), both had ValuEngine high 4 (Buy) ratings for forecast 1-year and 6-month returns. Both had dropped 30% in 2022 and our predictive model called for rebounds with six-month returns of better than 4%. Those two predictions appear to have been strong calls thus far. Both thus far in 2023 show returns above 15%.
ValuEngine Capital Management LLC (VECM) is pleased to announce the addition of Jordan Kimmel to the team as the new Chief Equity Strategist and portfolio manager. VECM is a Registered Investment Advisor (RIA) that invests based on the proprietary, quantitative research produced by ValuEngine Inc. It is an important partnership between two companies: ValuEngine conducts research, and ValuEngine Capital Management LLC actively trades client funds using this research.
To subscribe to our bulletins and receive content whenever it is published, subscribe at our blog HERE
Black Swan Research Coverage and Subscription Service
Event Calendar Updates
Nothing new on the Conference front-stay tuned
Visit our homepage for up to the minute Financial News, Quotes and our Latest Black Swan Connection Newsletter
-SMM Distribution Update
SMM Global Twitter Acct (Impressions last 30 days) 520
Direct Email * 220,000